Where this LCD applies
Each contract number is a jurisdiction on the remittance; the policy binds claims processed under these contracts and no others.
| Contract | Contractor | Type | States |
|---|---|---|---|
| 11201 | Palmetto GBA | A and B and HHH MAC | SC |
| 11301 | Palmetto GBA | A and B and HHH MAC | VA |
| 11401 | Palmetto GBA | A and B and HHH MAC | WV |
| 11501 | Palmetto GBA | A and B and HHH MAC | NC |
| 11202 | Palmetto GBA | A and B and HHH MAC | SC |
| 11302 | Palmetto GBA | A and B and HHH MAC | VA |
| 11402 | Palmetto GBA | A and B and HHH MAC | WV |
| 11502 | Palmetto GBA | A and B and HHH MAC | NC |
| 10111 | Palmetto GBA | A and B MAC | AL |
| 10211 | Palmetto GBA | A and B MAC | GA |
| 10311 | Palmetto GBA | A and B MAC | TN |
| 10112 | Palmetto GBA | A and B MAC | AL |
| 10212 | Palmetto GBA | A and B MAC | GA |
| 10312 | Palmetto GBA | A and B MAC | TN |
Billing and coding article A56605: diagnoses and procedure codes
Since 2019 the codes live in the companion article rather than the LCD. Billing and Coding A56605 (Billing and Coding: B-type Natriuretic Peptide (BNP) Testing) carries the diagnosis and procedure lists the contractor loads as the claims edit. CPT codes are shown as bare numbers because the descriptors are licensed by the AMA; HCPCS Level II descriptors are public and shown. Each article below opens its complete covered and non-covered ICD-10-CM lists, by group and with the contractor's group instructions, and the LCD code lookup answers whether one diagnosis is covered for one procedure code in a given state.
A56605: Billing and Coding: B-type Natriuretic Peptide (BNP) Testing (Billing and Coding, effective 2026-10-01)
- Covered ICD-10-CM codes
- 120
- 1 group
- Non-covered ICD-10-CM codes
- 0
- Procedure codes listed
- 1
- Full article
- cms.gov record
| ICD-10-CM | Description (FY2027) |
|---|---|
| E85.81 | Light chain (AL) amyloidosis |
| E85.82 | Wild-type transthyretin-related (ATTR) amyloidosis |
| E85.89 | Other amyloidosis |
| I11.0 | Hypertensive heart disease with heart failure |
| I13.0 | Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease, or unspecified chronic kidney disease |
| I13.2 | Hypertensive heart and chronic kidney disease with heart failure and with stage 5 chronic kidney disease, or end stage renal disease |
| I16.0 | Hypertensive urgency |
| I16.1 | Hypertensive emergency |
| I16.9 | Hypertensive crisis, unspecified |
| I1A.0 | Resistant hypertension |
| I20.0 | Unstable angina |
| I20.81 | Angina pectoris with coronary microvascular dysfunction |
| I20.89 | Other forms of angina pectoris |
| I21.01 | ST elevation (STEMI) myocardial infarction involving left main coronary artery |
| I21.02 | ST elevation (STEMI) myocardial infarction involving left anterior descending coronary artery |
| I21.09 | ST elevation (STEMI) myocardial infarction involving other coronary artery of anterior wall |
| I21.11 | ST elevation (STEMI) myocardial infarction involving right coronary artery |
| I21.19 | ST elevation (STEMI) myocardial infarction involving other coronary artery of inferior wall |
| I21.21 | ST elevation (STEMI) myocardial infarction involving left circumflex coronary artery |
| I21.29 | ST elevation (STEMI) myocardial infarction involving other sites |
| I21.3 | ST elevation (STEMI) myocardial infarction of unspecified site |
| I21.4 | Non-ST elevation (NSTEMI) myocardial infarction |
| I21.9 | Acute myocardial infarction, unspecified |
| I21.A1 | Myocardial infarction type 2 |
Procedure codes: 83880.
Coverage indications, limitations and medical necessity
B-type natriuretic peptide (BNP) and its precursor amino terminal (NT-proBNP) increase in patients with cardiac disease due to myocardial stress and volume overload as found in heart failure (HF). 3
When used in conjunction with other clinical information, the rapid measurement of levels of BNP or NT-proBNP is useful in establishing or excluding the diagnosis of HF as well as assessing the severity of HF in patients with acute dyspnea so that appropriate and timely treatment can be initiated. 8
This test may also be used to predict the long-term risk of cardiac events or death across the spectrum of acute coronary syndromes when measured in the first few days after an acute coronary event. 9
There is no conclusive evidence currently to warrant the repeated or serial use of BNP or NT-proBNP to alter or monitor treatment of HF especially in hospital inpatients. 16 Therefore, repeated or serial use of BNP or NT-proBNP measurements for monitoring and management of CHF are not a covered service. 17
The measurement of BNP as part of cardiovascular risk assessment panels, consisting of various combinations of biochemical, immunologic, hematologic, and molecular tests, is considered screening when performed on an asymptomatic patient, and, as such, is not a covered Medicare benefit. Please refer to MolDX: Biomarkers in Cardiovascular Risk Assessment L36129 Local Coverage Determination (LCD).
Summary of evidence (opening)
An estimated 92 million United States (US) adults have at least 1 type of cardiovascular disease (CVD) with estimates that over 40% of the US adult population is projected to have some form of CVD by 2030. 5 HF is a multifactorial systemic disease which affects over 26 million people worldwide and is increasing in prevalence. 4 Due to its high morbidity and mortality, the correct diagnosis of HF and cardiac dysfunction is paramount to determine appropriate treatment regimens.
Atrial natriuretic peptide (ANP), BNP and C-type natriuretic peptide (CNP) constitute the human natriuretic peptide family. BNP was originally isolated in pig brain tissue but was also found in the cardiac ventricles and to a lesser extent in the atria. Prior to its activation BNP and NT-proBNP are stored as a 108 amino acid polypeptide precursor proBNP in the ventricles. In response to volume expansion/overload and myocyte stretch, proBNP is cleaved to produce the biologically active 32 amino acid BNP and the 76 amino acid peptide NT-proBNP which are released into the vascular system where they can be detected. 1,2
The strongest indication for BNP measurement is distinguishing between cardiogenic and non-cardiogenic causes of dyspnea in an emergent setting. An elevated BNP level may indicate the need for further cardiac workup to determine the etiology of the patient’s symptoms. 10
A systematic review and meta-analysis of 19 studies involving 22 patient populations with a total of 9093 patients by Battaglia et al. in 2006 11 concluded that the use of BNP tests to rule out HF in different populations ranging from asymptomatic patients in a community setting to patients presenting with acute dyspnea to the emergency department found that negative results accurately rule out the diagnosis of HF especially if patients are at a relatively low risk of HF. B-type natriuretic peptide tests have the potential to guide clinical decisions, particularly in patients at lower risk in primary care and emergency departments. Applied early in the diagnostic process in patients with suspected cardiac failure, negative BNP test findings can help rule out HF and thus, avoid unnecessary referral to echocardiography. If the test result is positive, confirmation by echocardiography will generally be required. Early diagnosis of left ventricular dysfunction or HF can improve the prognosis of patients with left ventricular dysfunction without overt HF and patients with symptomatic HF.
The contractor cites 17 sources in the bibliography; the full summary and analysis of evidence are in the CMS record.
Dates, lineage and related policies
- Original determination effective
- 2015-10-01
- Current revision effective
- 2026-02-15
- Last reviewed by the contractor
- 2025-12-11
- MCD version
- 46
- Derived from
- L31546
Other related documents: A60382 (Response to Comments).
Using this policy on a claim
Match the documented indication to the covered indications above before the service is scheduled, carry a diagnosis from the article's covered list on the claim line (the diagnosis coverage checker tests one code pair against every article that applies in a state), and keep the elements the documentation section asks for in the record, because the contractor can request it later through medical review. A denial under this policy arrives as CARC 50 with remark N115; the LCD lookup guide walks through the appeal path and the Advance Beneficiary Notice rules, and the Palmetto GBA hub lists every other active policy from the same contractor.
The same policy title at other contractors
Contractors often adopt each other's policies and then revise them separately, so the criteria and the diagnosis lists drift apart. The topic comparison lines up every version.
For teams evaluating QuickIntell software
Where QuickIntell fits with this policy
If your team repeatedly reviews local coverage policies, explore QuickAuth for requirement checks, documentation and status tracking with staff oversight. Confirm the applicable policy, supported workflow and review responsibilities. Use QuickRCM to evaluate the separate claim and denial workflow.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions
What does LCD L34410 cover?
B-type natriuretic peptide (BNP) and its precursor amino terminal (NT-proBNP) increase in patients with cardiac disease due to myocardial stress and volume overload as found in heart failure (HF). 3 The full 221-word policy text is reproduced below from the Medicare Coverage Database export of November 12, 2026.
Which states does LCD L34410 apply to?
Palmetto GBA applies it to Medicare claims in 7 states: AL, GA, NC, SC, TN, VA, WV. It binds only that contractor; 4 other contractor versions of this title govern other jurisdictions, and elsewhere the same service is judged under the local contractor's own policy or, where none exists, claim by claim.
Which diagnosis codes support medical necessity under LCD L34410?
The companion billing and coding article A56605 lists 120 ICD-10-CM codes in 1 group that support medical necessity; the first 24 appear on this page, where the complete list opens by group with the contractor's group instructions.
How do I appeal a denial under LCD L34410?
A denial under LCD L34410 carries claim adjustment reason code 50 with remark code N115. Compare the documented indication with the policy's covered indications and article A56605's 120 covered diagnosis codes, then file a redetermination with Palmetto GBA within 120 days, record attached. If the service falls outside the policy, bill the patient only with a valid Advance Beneficiary Notice signed before the service.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- Medicare Coverage Database, current LCD exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file lcd.csvSHA-256 2e0eda3351aa3d47…
- Medicare Coverage Database, current Billing and Coding Articles exportVersion MCD release 2026-11-12 · effective 2026-11-08 · file article.csvSHA-256 b475751458564786…
- ICD-10-CM FY2027 code descriptionsVersion FY2027 · effective 2026-10-01 · file icd10cm_codes_2027.txtSHA-256 3c0583a38ee0e848…
Disclaimer
The policy text and code lists are reproduced from the CMS Medicare Coverage Database export as an operational reference. Verify against the current LCD and article on cms.gov before billing; coverage depends on the full record and the contractor. Not legal, clinical or billing advice.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.